Corey Casper, MD, MPH
Associate Professor, Allergy and Infectious Dis.
Adjunct Associate Professor, Epidemiology
Adjunct Associate Professor, Global Health
Assistant Member, Vaccine and Infectious Disease, Public Health Sciences, and Clinical Research Divisions, and Director, Uganda Program in Cancer and Infectious Diseases, Fred Hutchinson Cancer Research Center
Medical Director, Infection Control at Seattle Cancer Care Alliance
Dr. Casper divides his time between engaging in research, teaching and clinical care. His research efforts focus on the transmission, acquisition, natural history, pathophysiology and treatment of infection-associated cancers with a special focus on human herpesvirus 8 (HHV-8). His immunology work described the first comprehensively-validated serologic assay for detection of antibodies to HHV-8, the original description of neutralizing antibodies to HHV-8 and their role in development of Kaposi Sarcoma (KS), and the characterization of gamma-delta T-cell activity in persons with chronic HHV-infection. He then made the first descriptions of the symptoms and viral replication patterns of HHV-8-infected persons without KS. As part of this work, he studied HHV-8 transmission among couples discordant for HHV-8 infection, and also collaborated with researchers in HIV prevention studies to describe epidemiologic risk factors for acquiring HHV-8 in many different cohorts.
As part of his research into HHV-8, Dr. Casper described the successful use of antiviral therapy for the treatment of multicentric Castleman disease (MCD) and followed this by the first randomized trial of an antiviral against HHV-8. He also utilized information from a large primary HIV clinic to show that the majority of patients with KS in the highly active antiretroviral therapy era have persistent disease, despite the receipt of highly active antiretroviral therapy (HAART) and chemotherapy. This work has informed current and future studies evaluating the role of antiviral drugs in the treatment and prevention of infection-associated cancers.
In 2004, Dr. Casper initiated collaboration with physician-scientists at the Uganda Cancer Institute (UCI) and the Kampala Cancer Registry resulting in the formation of the Uganda Program in Cancer and Infectious Diseases (UPCID). As Director of this program, based at the Fred Hutchinson Cancer Research Center, he established a translational clinical research site in Kampala. This site currently has 23 ongoing studies examining the control of HHV-8 replication, biomarkers for the prediction of KS development and successful treatment, the immunogenetics of infection-associated cancers, treatment of KS and Burkitt lymphoma, the role of nutrition in the development and treatment of infection-related cancers, and the discovery of novel pathogens associated with cancer. Under Dr. Casper's direction, research is being bolstered with the addition of a new cancer clinic and hospital, a quickly expanding training program, and a state-of-the-art molecular diagnostics laboratory.
Fred Hutchinson Cancer Research Center
Program in Global Oncology
1100 Fairview Ave N, M1-B140
Seattle, WA 98109
Epidemiology; natural history; treatment of infections with human herpes virus 8 (also known as HHV-8, Kaposi's sarcoma-associated herpes virus or KSHV)
MPH, Epidemiology, University of Washington, SPH 2002
MD, Medicine (MD), Cornell University, Medical School 1997
SciVal Experts Page
In the news
Ugandan doctor helping reshape cancer care there (The Seattle Times)